CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- Open-market buys, last 90 days
- $226,500
- in 1 filing
- Open-market sales, last 90 days
- $4,661,919
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,435,419. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-09 | Kooij Louise Frederika Chief Accounting Officer | Sale | −53,104 | $25.31 | $1.3M | 111,896 |
| 2025-09-09 | Kooij Louise Frederika Chief Accounting Officer | Sale | −96,896 | $26.11 | $2.5M | 15,000 |
| 2025-09-09 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) | −150,000 | 280,015 | ||
| 2025-09-08 | Topper James N Director | Purchase | +1,260 | $24.99 | $31K | 3,027,864 |
| 2025-09-03 | Kooij Louise Frederika Chief Accounting Officer | Sale | −18,073 | $25.09 | $453K | 15,000 |
| 2025-09-02 | Kooij Louise Frederika Chief Accounting Officer | Option exercise | +18,073 | 33,073 | ||
| 2025-09-02 | Kooij Louise Frederika Chief Accounting Officer | Option exercise · Option (right to buy) | −18,073 | 0 | ||
| 2025-08-25 | Kooij Louise Frederika Chief Accounting Officer | Sale | −8,269 | $24.86 | $206K | 15,000 |
| 2025-08-22 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −42,342 | $25.08 | $1.1M | 76,960 |
| 2025-08-22 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −7,658 | $25.49 | $195K | 69,302 |
| 2025-08-21 | Kastelein Johannes Jacob Pieter Chief Scientific Officer | Sale | −50,000 | $24.29 | $1.2M | 119,302 |
| 2025-08-11 | Topper James N Director | Purchase | +471 | $23.98 | $11K | 3,026,604 |
| 2025-07-16 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +51,043 | $10.90 | $556K | 95,043 |
| 2025-07-16 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −51,043 | $21.10 | $1.1M | 44,000 |
| 2025-07-16 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −51,043 | 162,702 | ||
| 2025-07-15 | Kling Douglas F Chief Operating Officer | Option exercise 10b5-1 | +47,569 | $10.90 | $519K | 91,569 |
| 2025-07-15 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −44,025 | $21.38 | $941K | 47,544 |
| 2025-07-15 | Kling Douglas F Chief Operating Officer | Sale 10b5-1 | −3,544 | $22.12 | $78K | 44,000 |
| 2025-07-15 | Kling Douglas F Chief Operating Officer | Option exercise · Option (right to buy) 10b5-1 | −47,569 | 213,745 | ||
| 2025-06-25 | Topper James N Director | Purchase | +1,260 | $18.26 | $23K | 3,026,133 |
Page 7 of 15 · 300 trades